SCHEMBL8097767

SCHEMBL8097767

CCN1CCNCC1OC(c1ccccc1)c1ccccc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.44
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
SLC6A2 P23975 7/20 0.39
SLC6A4 P31645 7/20 0.39
SLC6A3 Q01959 5/20 0.39
CYP2D6 P10635 3/20 0.39
KCNH2 Q12809 2/20 0.39
CYP3A4 P08684 2/20 0.39
SLC22A2 O15244 1/20 0.39
SLC22A1 O15245 1/20 0.39
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
ADRA2A P08913 1/20 0.39
CHRM1 P11229 1/20 0.39
ADRA2B P18089 1/20 0.39
CHRM3 P20309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6255525 0.89 SIGMAR1 (0.43) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL1577933 0.78 SIGMAR1 (0.46) MEN1KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL1578048 0.78 TDP1 (0.37) SLC6A2SLC6A3CYP2D6CYP3A4CHRM2
SCHEMBL8107386 0.74 MEN1 (0.40) CHRNA7MEN1KMT2ASLC6A2SLC6A4
SCHEMBL8938186 0.72 SLC6A2 (0.42) CHRNA7SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL27889106 0.72 HRH1 (0.40) SLC6A2SLC6A4SLC6A3KCNH2HTR2C
SCHEMBL4189112 0.71 SLC6A2 (0.48) CHRNA7SLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL8097776 0.68 CHRNA7 (0.79) CHRNA7MEN1KMT2ASLC6A2SLC6A4
SCHEMBL8097765 0.68 SLC6A2 (0.48) CHRNA7MEN1KMT2ASLC6A2SLC6A4
SCHEMBL27712059 0.67 SMN1; SMN2 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0983222-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 2000-03-08 EP disclosed
WO-1998052898-A9 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 1999-04-01 WO disclosed
WO-1998052898-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 1998-11-26 WO disclosed